Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Table 3 Treatment-related model inputs

Regimen	Duration (weeks)	Acquisition cost		SVR			Disutility
Regimen	Duration (weeks)	Per week (£)	Source	Population	%	Source	Mean	Source
DCV + SOF	12	4958.37	Monthly index of medical specialities	Treatment-naïve	96.4	MAIC [30]	0.035	Estimated from [37]
				Treatment-experienced	83.2
				Interferon-ineligible/intolerant	88.8^a
SOF + RBV	24	2982.19	Monthly index of medical specialities	Treatment-naïve	94.3	MAIC [30]	0.048	Estimated from [38]
				Treatment-experienced	78.6
				Interferon-ineligible/intolerant	85.2^a
No treatment	NA	0	NA	Interferon-ineligible/intolerant	0	Assumed	0	NA

DCV daclatasvir, NA not applicable, MAIC matching-adjusted indirect comparison, RBV ribavirin, SOF sofosbuvir, SVR sustained virologic response
^aAssumed, based on pooled treatment-naïve and treatment-experienced subgroups

ISSN: 1478-7547